Tag: Editorial Message

Editorial Message and Issue Highlights–Vol. 15, No. 11–12, November-December 2018

Editorial Message and Issue Highlights–Vol. 15, No. 11–12, November-December 2018

| November 1, 2018

Dear Colleagues: Welcome to the November–December issue of Innovations in Clinical Neuroscience (ICNS). We start this issue with an article by Aboraya et al titled “Measurement-based Care in Psychiatry—Past, Present, and Future.” Here the authors define and describe measurement-based care (MBC) in psychiatry as well discuss the research supporting its use in clinical practice. Barriers […]

Continue Reading

Editorial Message and Issue Highlights–Vol. 15, No. 9–10, September-October 2018

Editorial Message and Issue Highlights–Vol. 15, No. 9–10, September-October 2018

| October 1, 2018

Dear Colleagues: Welcome to the September–October 2018 issue of Innovations in Clinical Neuroscience (ICNS). We start this issue with a systematic review by Bart et al titled, “The Assessment and Measurement of Wellness in the Clinical Medical Setting: A Systematic Review.” Here, investigators reviewed the published literature in an attempt to answer the following: 1) […]

Continue Reading

Editorial Message and Issue Highlights–Vol. 15, No. 7–8, July-August 2018

Editorial Message and Issue Highlights–Vol. 15, No. 7–8, July-August 2018

| July 1, 2018 | 0 Comments

Dear Colleagues: Welcome to the July–August 2018 issue of Innovations in Clinical Neuroscience (ICNS). We start this issue with a report by Brennan et al titled, “Implementation of the Electronic Columbia-Suicide Severity Rating Scale (eCSSRS™) Across Four Phase IIIb Clinical Trials in HIV-infected Individuals (ARIA, STRIIVING, DAWNING and INSPIRING).” Here, researchers assessed site perspectives on […]

Continue Reading

Editorial Message and Issue Highlights–Vol. 15, No. 5–6, May-June 2018

| May 1, 2018 | 0 Comments

Dear Colleagues: Welcome to the May–June 2018 issue of Innovations in Clinical Neuroscience (ICNS). We start the issue with a timely review article by Touma and Scarff titled, “Valbenazine and Deutetrabenazine for Tardive Dyskinesia (TD).” Here, the authors discuss the two drugs, which were recently approved by the United States Food and Drug Administration (FDA) […]

Continue Reading

Editorial Message and Issue Highlights–Vol. 15, No. 3–4, March-April 2018

Editorial Message and Issue Highlights–Vol. 15, No. 3–4, March-April 2018

| April 1, 2018 | 0 Comments

Dear Colleagues: Welcome to the March–April 2018 issue of Innovations in Clinical Neuroscience (ICNS). We are excited to lead this edition of ICNS with an exciting commentary by Dr. Michael Ehlers, Head of Research and Development at Biogen (Cambridge, Massachusetts). In his article, “Neuroscience is the Next Oncology,” Dr. Ehlers explores  “the signs of a […]

Continue Reading